Chemiluminescence Immunoassay for Quantitative Analysis of Prostate Specific Antigen Complexed to α1-Antichymotrypsin in Human Serum

被引:2
作者
Zhou You-Jun [1 ]
Li Jiao-Xia [1 ]
Cheng Hui-Jun [1 ]
Yang Qiao-Fen [1 ]
He Mei-Qiong [1 ]
Guo Li-Ping [1 ]
Deng Zhi-Yong [2 ]
机构
[1] Kunming Med Univ, Nucl Med, Yan An Hosp, Kunming 650051, Peoples R China
[2] Kunming Med Univ, Affiliated Hosp 3, Nucl Med, Kunming 650051, Peoples R China
关键词
Prostate-specific antigen complexed to alpha 1-antichymotrypsin; Prostate cancer; Chemiluminescence; enzyme immunoassay; Horseradish peroxidase; TOTAL PSA; CANCER; ASSAY; BLOOD; FORMS;
D O I
10.11895/j.issn.0253.3820.150937
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Eight mouse hybridoma cell lines which stably secreted monoclonal antibodies (McAbs) against human prostate. specific antigen-alpha 1-antichymotrypsin complex (PSA-ACT) were obtained through hybridoma technique. After purification, the immunological characters of 8 McAbs were identified and classified by epitopes analysis through indirect enzyme. linked immunosorbent assay (ELISA). A pair of McAbs was chosen from above 8 McAbs, based on which a highly sensitive, simple and rapid chemiluminescence enzyme immunoassay (CLEIA) was developed for determination of PSA-ACT in human serums using the lumino-H2O2 reaction catalyzed by horseradish peroxidase (HRP) as the chemiluminescence system. Several experiment factors such as coating buffer, coating concentration, dilution ratio of PSA-ACT-HRP complex, incubation time, immunoreaction protocol and chemiluminescence reaction time were optimized. The results showed that the linear range of the proposed method for PSA-ACT determination was 0-40 ng/mL (R-2 = 0. 9943), with the detection limit of 0. 53 ng/mL. The inter. assay relative standard deviations (RSDs) were 4. 6%-6. 6%, and intra. assay RSDs were 5. 7%-8. 0%. The recoveries of PSA-ACT at three spiked levels in serum samples were 95. 4%-104. 2%. The proposed method exhibited a cross. reactivity of 0. 6% with free. PSA. The proposed method is stable, sensitive, rapid and simple, and provides a foundation for the development of PSA-ACT CLEIA kit and shows great value in clinical auxiliary diagnosis of prostate cancer.
引用
收藏
页码:1209 / 1214
页数:6
相关论文
共 32 条
  • [1] CHANG Xiao-Tong, 2004, CHINA J MODERN MED, V14, P24
  • [2] CHEN ZX, 1995, CLIN CHEM, V41, P1273
  • [3] SERUM PROSTATE-SPECIFIC ANTIGEN COMPLEXED TO ALPHA-1-ANTICHYMOTRYPSIN AS AN INDICATOR OF PROSTATE-CANCER
    CHRISTENSSON, A
    BJORK, T
    NILSSON, O
    DAHLEN, U
    MATIKAINEN, MT
    COCKETT, ATK
    ABRAHAMSSON, PA
    LILJA, H
    [J]. JOURNAL OF UROLOGY, 1993, 150 (01) : 100 - 105
  • [4] Du G M, 2013, MOL BIOL TISSUE CULT, V14, P816
  • [5] Du G M, 2013, MOL BIOL TISSUE CULT, V14, P837
  • [6] HU Ling-Mei, 2012, CHINESE J CELL BIOL, V25, P14
  • [7] Hu Y, 1995, J UROLOGY, V3, P1004
  • [8] Prostate-specific antigen (PSA) complexed to α1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL
    Kobayashi, T
    Kamoto, T
    Nishizawa, K
    Mitsumori, K
    Ogura, K
    Ide, Y
    [J]. BJU INTERNATIONAL, 2005, 95 (06) : 761 - 765
  • [9] Lei Z, 2013, PROSTATE, V73, P219
  • [10] LI Song, 1998, FOREIGN MEDICAL SCI, V18, P168